Ovid Therapeutics Enters Agreement With Immedica Pharma AB For Sale Of Future Ganaxolone Royalties
June 25 (Reuters) - Ovid Therapeutics Inc OVID.O:
OVID THERAPEUTICS ENTERS AGREEMENT WITH IMMEDICA PHARMA AB FOR SALE OF FUTURE GANAXOLONE ROYALTIES
OVID THERAPEUTICS INC - IMMEDICA TO PAY $7 MILLION FOR GANAXOLONE ROYALTY RIGHTS
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
ORCL Stock: Why Oracle May Be the Beaten-Down Tech Giant Ready for a Comeback

Nvidia Makes First Bet on Legal AI, Invests $50 Million in Legora

Palantir Q1 2026 Earnings Preview — Is PLTR a Buy at $144?

POET Technologies Stock Could Still Surge in 2026, but the Bar for a Breakout Is Higher Now

From Underdog to AI Infrastructure Leader: Is AMD Poised for Growth in 2026?

Tradingkey







